Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026
Jade Biosciences presented preclinical data at EADV 2026 for JADE301, a half-life-extended anti-IFN-β antibody in development for dermatomyositis. The data showed roughly 2.5-fold higher IFN-β affinity and potency than a dazukibart comparator, an approximately 25-day subcutaneous half-life in non-human primates, and predicted human SC bioavailability of 73%–75% versus ~43%–44% for dazukibart. JADE301 was well tolerated in a GLP toxicology study at all doses tested.
Key figures
- Drug Name
- JADE301
- Phase Of Trial
- Phase 1
- Phase1 start
- Q4 2026
- Binding kd p M
- 11.3 pM
- Pstat ic50 p M
- 13 pM
- Phase1 subjects
- 24
- Phase1 interim data
- second half of 2027
- Nhp half life iv days
- approximately 30-day
- Nhp half life sc days
- approximately 25-day
- Dm prevalence us adults
- approximately 50,000
- Mx1 ic50 fibroblasts p M
- 11 pM
- Predicted human sc bioavailability
- approximately 73%–75%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.